The drug, Leqembi, has been shown to slow the decline in memory and thinking that defines Alzheimer’s. But there are risks, including the need for infusions and the possibility of brain swelling.
U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh.U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks
Leqembi, from Japan’s Eisai and its U.S. partner Biogen, is a rare success in a field accustomed to failed experimental treatments for the incurable condition Leqembi, from Japan’s Eisai and its U.S. partner Biogen, is a rare success in a field accustomed to failed experimental treatments for the incurable condition. The delay in cognitive decline brought about by the drug likely amounts to just several months, but Dr. Joy Snider and some other experts say it could still meaningfully improve people’s lives.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA approves Leqembi, Alzheimer's drug that modestly slows diseaseALZHEIMER'S DRUG: The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology. MORE:
Consulte Mais informação »
Second Alzheimer’s treatment showing modest benefits for patients approved by FDAThe FDA has granted accelerated approval to a second Alzheimer’s drug that trial data show offers modest benefits to patients.
Consulte Mais informação »
US approves breakthrough drug Leqembi to treat Alzheimer'sLeqembi and Aduhelm, which were jointly developed by Japan's Eisai and Biogen of US 'represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease,' says Food and Drug Administration.
Consulte Mais informação »
Alzheimer’s drug that slows cognitive decline gets FDA approvalThe drug, lecanemab, removes a sticky protein from the brain called amyloid beta, which is thought to play a key role in the memory-robbing illness.
Consulte Mais informação »
FDA Approves Alzheimer's Drug That Modestly Slows DiseaseThe drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s.
Consulte Mais informação »
FDA OKs Alzheimer’s drug that modestly slows disease“This drug is not a cure. It doesn’t stop people from getting worse, but it does measurably slow the progression of the disease,” said Dr. Joy Snider, a neurologist at Washington …
Consulte Mais informação »